Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CSPC Pharmaceutical GroupXTER:CVG 90 Equity-to-Asset is 0.74 as of Dec. 2025, which is 4% above its 10-year median of 0.71. GuruFocus rates XTER:CVG with a GF Score™ of 90/100 and a GF Value™ of €0.32. The stock has 3 warning signs investors should review. Among 1,008 Drug Manufacturers companies, CSPC Pharmaceutical Group ranks better than 61.41% on this metric.
CSPC Pharmaceutical Group (XTER:CVG) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
CSPC Pharmaceutical Group Equity-to-Asset Related Terms
CSPC Pharmaceutical Group Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:CVG vs LLY, JNJ, ABBV: Equity-to-Asset Comparison
For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSPC Pharmaceutical Group Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where CSPC Pharmaceutical Group's Equity-to-Asset falls into.
CSPC Pharmaceutical Group Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
CSPC Pharmaceutical Group's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSPC Pharmaceutical Group (XTER:CVG) has a Equity-to-Asset of 0.74 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CSPC Pharmaceutical Group and its competitors. This is near median its historical median of 0.71. Over the past decade, CSPC Pharmaceutical Group's Equity-to-Asset has ranged from 0.62 to 0.75. According to the industry distribution chart, CSPC Pharmaceutical Group ranks #389 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 38.6%.
Is CSPC Pharmaceutical Group's Equity-to-Asset too high?
CSPC Pharmaceutical Group's current Equity-to-Asset of 0.74 is near median its 10-year median of 0.71. Over the past 10 years, this metric has ranged from a low of 0.62 to a high of 0.75. The Drug Manufacturers industry median Equity-to-Asset is 0.60. CSPC Pharmaceutical Group's value of 0.74 is 23.3% above this industry median. Based on the distribution chart, CSPC Pharmaceutical Group ranks #389 out of 1008 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, CSPC Pharmaceutical Group has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does CSPC Pharmaceutical Group's Equity-to-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, CSPC Pharmaceutical Group ranks #389 out of 1008 companies for Equity-to-Asset. This puts CSPC Pharmaceutical Group in the upper half of its industry. The industry median Equity-to-Asset is 0.60. CSPC Pharmaceutical Group's value of 0.74 is 23.3% above this benchmark. Historically, CSPC Pharmaceutical Group's own Equity-to-Asset has ranged from 0.62 to 0.75 over the past decade. While the company's 10-year median is 0.71 vs. the industry median of 0.60, CSPC Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSPC Pharmaceutical Group's current Equity-to-Asset of 0.74 is 23.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CSPC Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSPC Pharmaceutical Group's current Equity-to-Asset is 0.74, which is near median its own 10-year median of 0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSPC Pharmaceutical Group stock overvalued right now?
CSPC Pharmaceutical Group (XTER:CVG) has a current Equity-to-Asset of 0.74. The stock's GF Value™ is €0.32, compared to a current price of €0.40 — trading 25% above its estimated fair value. The current Equity-to-Asset is 0.74, which is near median its 10-year median of 0.71 and 23.3% above the Drug Manufacturers industry median of 0.60. CSPC Pharmaceutical Group's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For CSPC Pharmaceutical Group (XTER:CVG), the current Equity-to-Asset is 0.74 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSPC Pharmaceutical Group (XTER:CVG) Overvalued in 2026?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be overvalued.
The current stock price of €0.40 is trading 25% above its estimated GF Value™ of €0.32.
Key valuation signals for XTER:CVG:
Equity-to-Asset: 0.74 (near median its 10-year median of 0.71)
GF Value™: €0.32 vs. price of €0.40 (25% above fair value)
Industry Position: 23.3% above the Drug Manufacturers median (#389 of 1008)
No single metric tells the full story. See the XTER:CVG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
90GF Score
Get the complete analysis for XTER:CVG
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:CVG has been successfully added to your 
